The proposed model incorporating short diameter, lymphocyte ratio, CD3+ T cell count, and CD4+ T cell ratio demonstrates significant potential in differentiating benign from malignant lymphadenopathy in HIV patients. The gene discussed is CD4; the disease is cancer.